Challenge
In 2021, a midsize Pharma company was planning to update its Medical Affairs structure and practices, in order to keep up (and possibly get ahead of) the changes, accelerated by the pandemic, in customer needs and medical affairs priorities, strategies, activities and methods. The goal of the project was to info...
Challenge:
The Head of Medical Affairs (MA) in a midsize company was not satisfied with the level of collaboration between his organization and commercial colleagues who did not fully recognize the value of the MA contribution to the success of the company. The goal of the project was to understand and address the root ca...
The Challenge
One of the most important inputs into selecting which development programs should be fully funded and accelerated to market is the confidence in knowing that a market will be there to ensure commercial success.- Many approved products are not necessarily commercial successes, and...
Challenge
A large biotech company had invested significant resources in reimbursement support, including Field Reimbursement Managers (FRMs). The organization was frustrated by the lack of quantitative metrics to evaluate and assess the effectiveness of the FRMs and asked BCA to develop an approach to address this gap.Solution:
... Challenge
Large pharma organization desired a radical shift to customer-driven models utilizing the following criteria:- Reducing traditional sales representative headcount by 50%,
- Deploying new account management resources against key influencers including payers, providers, employers, academia, ...
Challenge:
The client, a large U.S.-based pharmaceutical company had the leading product in a mature market. There were six products in category, including a new low-price entry. The key issue the organization faced was the lack of clinical differentiation among products which had resulted in ancillary product features being the primary m...
Background:
A U.S. Biotech organization had fielded a customer-facing team of Community Liaisons (~30) to augment the sales efforts for their HIV franchises within targeted markets. The Community Liaisons (CLs) responsibilities include the following:- Focus on the timely delivery of clinical information on the treatment of HIV...
Challenge: SCYNEXIS was launching Brexafemme, a pill treatment for oral treatment designed to eliminate the yeast causing infection in September 2021. Brexafemme is The first modern prescription oral treatment the market. They had not IT strategy and limited Systems and no support IT for a Commercial launch Solution: Implem...
Challenge: Callidatas US was launching Nefecon, a capsule treatment for IgA Nephropathy (IgAN) for the US in November 2021. Nefecon is an orphan drug for rare diseases. They also needed to be preparing for Fruquintinib in 2023. They had no IT strategy nor any Systems in place to enable and support the launch. The commercialization would ...